Acutaas Chemicals Ltd (NSE: ACUTAAS) and Natco Pharma Ltd (NSE: NATCOPHARM) are both listed in the Medicinal Chemicals and Botanical Products industry. Acutaas Chemicals has a market capitalisation of ₹32,068 Cr and Natco Pharma ₹15,869 Cr, as of 16 Nov 2026. Their P/E ratios are 92.2 and 10.2 respectively. Return on equity is 23.52% for Acutaas Chemicals and 16.85% for Natco Pharma. Over one year, Acutaas Chemicals's share price is up 128.8% and Natco Pharma's is up 1.0%.
| Metric | Acutaas Chemicals | Natco Pharma |
|---|---|---|
| NSE Symbol | ACUTAAS | NATCOPHARM |
| BSE Code | 543349 | 524816 |
| Share Price | ₹4,055.00 | ₹808.00 |
| Market Cap | ₹32,068 Cr | ₹15,869 Cr |
| P/E Ratio | 92.2 | 10.2 |
| Return on Equity | 23.52% | 16.85% |
| Return on Assets | 15.74% | 7.98% |
| Dividend Yield | 0.06% | 0.56% |
| Beta (1Y) | 0.31 | 0.17 |
| 1-Year Price Change | +128.8% | +1.0% |
| 3-Month Price Change | +29.8% | -14.8% |
| 52-Week Range | ₹1,602.50 – ₹4,130.00 | ₹773.60 – ₹1,226.80 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹437 Cr | ₹967 Cr |
| Quarterly Net Profit | ₹123 Cr | ₹203 Cr |
| Net Margin | 28.2% | 20.9% |
| EPS (Basic, Quarter) | ₹15.29 | ₹11.31 |
| Results Basis | consolidated | consolidated |
| Headquarters | Surat, Gujarat | Hyderabad, Telangana |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson’s, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist chemicals to semiconductor applications; electrol…
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and in…
Acutaas Chemicals has a market capitalisation of ₹32,068 Cr, against ₹15,869 Cr for Natco Pharma as of 16 Nov 2026, about 2.0 times the size by market cap.
Acutaas Chemicals has a P/E of 92.2 and Natco Pharma a P/E of 10.2 as of 16 Nov 2026.
Acutaas Chemicals has a return on equity of 23.52% and Natco Pharma 16.85%.
Acutaas Chemicals's share price is up 128.8% over one year and Natco Pharma's is up 1.0%.
Acutaas Chemicals reported revenue of ₹437 Cr and net profit of ₹123 Cr for Q2 FY27. Natco Pharma reported revenue of ₹967 Cr and net profit of ₹203 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.